Somatic MED12 Mutations in Myometrial Cells.

Area of Science:

• Gynecology
• Molecular Biology
• Genetics

Background:

• Uterine leiomyomas (LMs) are common benign tumors, with over 70% harboring MED12 mutations.
• Myometrial cells are the cell of origin for LMs, but their MED12 mutation status is largely unknown.
• Detecting low-frequency mutations requires sensitive sequencing methods.

Purpose of the Study:

• To investigate the mutation burden of MED12 in non-neoplastic myometrial cells.
• To determine if MED12 mutations are present in the cell of origin for uterine leiomyomas.
• To explore the potential role of early somatic MED12 mutations in leiomyoma development.

Main Methods:

• Utilized duplex deep sequencing analysis (DDS) for high-sensitivity mutation detection (<0.1%).
• Dissected tumor-free myometrial tissue and extracted genomic DNA.
• Targeted capture of MED12 exon 2 and TP53 exon 5 (control) followed by DDS.

Main Results:

• DDS detected a high frequency of MED12 mutations in myometrial cells, predominantly at the c.130-131 sites.
• Baseline mutation levels in other MED12 regions and the TP53 hotspot were low.
• This is the first report of non-random MED12 mutation accumulation in non-neoplastic myometrial cells.

Conclusions:

• Non-neoplastic myometrial cells exhibit a significant burden of MED12 mutations at specific hotspots.
• These findings provide molecular evidence for early somatic MED12 mutations in myometrial cells.
• Early MED12 mutations may contribute to the cellular origin of uterine leiomyomas.